Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

Cancer

Volumn 115, Issue 18, 2009, Pages 4104-4109

  Sonpavde, Guru ^a   Goldman, Bryan H ^b   Speights, V O ^c   Lerner, Seth P ^a   Wood, David P ^d   Vogelzang, Nicholas J ^e   Trump, Donald L ^f   Natale, Ronald B ^g   Grossman, H Barton ^h   Crawford, E David ⁱ  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e NEVADA CANCER INSTITUTE   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

Author keywords

Bladder cancer; Neoadjuvant chemotherapy; Overall survival; Pathologic complete response

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BLADDER CANCER; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; DOXORUBICIN; HUMANS; LYMPH NODE EXCISION; METHOTREXATE; NEOADJUVANT THERAPY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 70149108534     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24466     Document Type: Article

References (29)

1. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [erratum in N Engl J Med. 2003;349:1880]. N Engl J Med. 2003;349:859-866.
2. [no authors listed]. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International Collaboration of Trialists [erratum in Lancet. 1999;354:1650]. Lancet. 1999;354:533-540.
3. Hall RR, on behalf of the International Collaboration of Trialists of the MRC Advanced Bladder Cancer Group, MRC Clinical Trials Unit, London, UK. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer [abstract]. Proc Am Soc Clin Oncol. 2002;21. Abstract 710.
4. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927-1934.
5. Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22:2781-2789.
6. Dotan ZA, Bajorin DF, Grossman BH, Herr HW. Optimal combined modality treatment improves outcome of locally advanced bladder cancer: analysis of SWOG 8710. ASCO Annual Meeting Proceedings. J Clin Oncol. 2005;23(16 suppl, part I of II):4531.
7. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-469.
8. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019-2027. (Pubitemid 46622110)
9. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940-1949. (Pubitemid 46638994)
10. Kurosumi M. Significance of histopathological evaluation in primary therapy for breast cancer - recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer. 2004;11:139-147.
11. Kuroi K, Toi M, Tsuda H, et al. Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. Biomed Pharmacother. 2005;59:S387-S392. (Pubitemid 43303911)
12. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676-2685. (Pubitemid 46179457)
13. Jones RL, Lakhani SR, Ring AE, et al. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer. 2006;94:358-362.
14. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25:2650-2655. (Pubitemid 47123169)
15. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25: 4414-4422. (Pubitemid 350013847)
16. Jeruss JS, Mittendorf EA, Tucker SL, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008;26:246-252.
17. Poulsen A, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol. 1998;160:2015-2019. (Pubitemid 128703604)
18. Smith IE, Heys SD, Hutckeon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456-1466. (Pubitemid 34260523)
19. von Minckwitz G, Kummel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100:542-551.
20. Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991;145:459-464.
21. Lehmann J, Franzaring L, Thuroff J, et al. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int. 2006;97:42-47.
22. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol. 1996;155:495-499. (Pubitemid 26023531)
23. Studer UE, Bacchi M, Biedermann C, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol. 1994;152:81-84. (Pubitemid 24175706)
24. Donat MS, Shabsigh A, Savage C, et al. The impact of postoperative complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy for invasive or node positive bladder cancer [abstract]. Proceedings of the American Urological Association Annual Meeting, Orlando, Florida, May 17-22, 2008. Abstract 848.
25. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005;11:2625-2636. (Pubitemid 40569463)
26. Takata R, Katagiri T, Kanehira M, et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 2007;98:113-117. (Pubitemid 44803929)
27. Font A, Taron M, Costa C, et al. BRCA1 mRNA expression in patients (p) with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy [abstract]. J Clin Oncol. 2008;26(suppl). Abstract 5021.
28. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167-170. (Pubitemid 47232611)
29. Jones RL, Salter J, A'hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. In press.